# MW151-101: First-in-human Study of MW151

> **NCT04120233** · PHASE1 · COMPLETED · sponsor: **Linda Van Eldik** · enrollment: 40 (actual)

## Conditions studied

- Drug Toxicity

## Interventions

- **DRUG:** Placebo
- **DRUG:** MW151, 10mg
- **DRUG:** MW151, 20mg
- **DRUG:** MW151, 40mg
- **DRUG:** MW151, 80mg
- **DRUG:** MW151, 160mg

## Key facts

- **NCT ID:** NCT04120233
- **Lead sponsor:** Linda Van Eldik
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-10-22
- **Primary completion:** 2021-09-16
- **Final completion:** 2021-09-16
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2022-12-30

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04120233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04120233, "MW151-101: First-in-human Study of MW151". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04120233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*